Diabetic ketoacidosis due to pembrolizumab
10.3760/cma.j.cn114015-20210120-00086
- VernacularTitle:帕博利珠单抗致糖尿病酮症酸中毒
- Author:
Tiantian WEI
1
;
Zhen LIU
;
Zhongkui WANG
;
Jing PENG
;
Jing ZHANG
Author Information
1. 山东省济宁医学院附属医院药学部，济宁 272000
- Publication Type:Journal Article
- Keywords:
Diabetic ketoacidosis;
Immune checkpoint inhibitors;
Pembrolizumab
- From:
Adverse Drug Reactions Journal
2021;23(12):649-650
- CountryChina
- Language:Chinese
-
Abstract:
A 68-year-old male patient with advanced lung squamous cell carcinoma received intravenous infusion of pembrolizumab 200 mg once every 3 weeks. One week after the 4th IV infusion of pembrolizumab, the patient developed nausea and vomiting. Laboratory tests showed blood potassium 7.39 mmol/L, fasting blood glucose 28.1 mmol/L, β-hydroxybutyric acid 3.23 mmol/L, arterial blood pH 7.16, and bicarbonate 7.5 mmol/L. The patient was diagnosed as diabetic ketoacidosis, which was considered to be associated with pembrolizumab. After 8 days of treatments such as lowering blood sugar and correcting electrolyte disorder, his nausea and vomiting disappeared. Laboratory tests showed blood potassium 3.65 mmol/L, fasting blood glucose 7.5 mmol/L, β-hydroxybutyric acid 0.38 mmol/L, and bicarbonate 25.2 mmol/L.
